2017 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle
09/26/17Machelle Sanders Appointed to Novan Board of Directors
MORRISVILLE, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the appointment of Machelle Sanders to the Company’s Board of Directors. Ms. Sanders is a former biopharmaceutical executive with extensive experience in quality, manufacturing and operations. She is currently Secretary of the N.C. Department of Administration and, prior to her appointment as Secretary earlier this year, she served in several positions at Biogen including ... 
09/25/17Novan Conducts Guidance Meeting with FDA on SB204 Development Program
MORRISVILLE, N.C., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has concluded a guidance meeting with the U.S. Food and Drug Administration (FDA) regarding SB204 for the treatment of acne vulgaris. The FDA advised that an additional pivotal trial should be conducted. Given the need for the additional clinical study, the agency treated this meeting as a guidance meeting rather than a pre-NDA meeting.  The Company anticipates rec... 
08/16/17Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors
MORRISVILLE, N.C., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that Paula Brown Stafford has been appointed to the Company’s Board of Directors, effective immediately. Ms. Stafford joined Novan in March of this year and will continue as the Chief Development Officer, leading clinical development with a focus on the execution of clinical trials, the further development of clinical operations and the establishment of medical, statistical... 
07/25/17Novan Announces Corporate Update Conference Call and Webcast
MORRISVILLE, N.C., July 25, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, Aug. 2, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the ... 
07/07/17Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology
MORRISVILLE, N.C., July 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic, safety and efficacy data for SB204, an investigational once-daily, topical monotherapy for the treatment of acne vulgaris, will be presented at the 13th World Congress of Pediatric Dermatology in Chicago, Illinois. New data from a post-hoc analysis of Novan’s recently completed Phase 3 pivotal trials, conducted in a subset of only adolescent subjects, ... 
06/05/17Novan Announces Leadership Adjustments and Business Update
Aligns existing talent and experience with next phase Accelerates broadening the application of the science Intends regulatory follow up with regard to SB204 for acne Resource alignment to near term focus Strengthening the balance sheet an important focus MORRISVILLE, N.C., June 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced adjustments to its executive leadership team with immediate effect. These actions will accelerate a rep... 
05/12/17Novan Reports First Quarter 2017 Financial Results
MORRISVILLE, N.C., May 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the Company’s financial results for the first quarter of 2017. Total operating expenses for the three months ended Mar. 31, 2017, were approximately $11.5 million, which includes research and development, or R&D, expenses totaling approximately $7.0 million and general and administrative, or G&A, expenses totaling approximately $4.5 million. Total operating expens... 
04/27/17Novan Presents Safety Data for SB204 Program
No Detectable Systemic Exposure in Three Pharmacokinetic Clinical Trials MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic data for SB204, a once-daily, topical monotherapy for the treatment of acne vulgaris, will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology in Portland, Oregon. In three pharmacokinetic clinical trials conducted in patients with moderate to sev... 
04/27/17Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
Poster Presentations Provide Mechanistic Evidence for SB414 as a Potential Treatment for Psoriasis and Atopic Dermatitis MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing cream in development for the treatment of inflammatory skin diseases such as psoriasis and atopic dermatitis, will be presented at the 76th Annual Meeting of the Society for Inv... 
04/12/17Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Clinical Evidence of Antifungal Activity Supports Antimicrobial Breadth of Nitric Oxide Platform MORRISVILLE, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced positive topline results from the Company’s Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan is developing SB208 as a broad-spectrum antif... 
04/04/17Novan Welcomes Key Opinion Leaders to New Advisory Council
Dr. Lawrence Eichenfield to Chair Expert Group Focused on Expanding the Breadth of Nitric Oxide Therapies in DermatologyMORRISVILLE, N.C., April 04, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. Novan has recruited these leading physicians based on their reputations as clinical experts to provide medical advice and drug-develop... 
03/22/17Novan Reshapes Executive Management Team
Former Quintiles Executive Paula Brown Stafford Joins Novan as Chief Development Officer Stanley Hollenbach Promoted to Senior Vice President of Research and Development William L. Hodges Appointed as Interim Chief Financial Officer on Departure of Richard Peterson MORRISVILLE, N.C., March 22, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced adjustments to the executive management team that aim to strengthen the Company’s clinical operations in... 
03/20/17Novan Reports Fourth Quarter and Full Year 2016 Financial Results
Company Provides Updates on Upcoming Milestones Across the Development Platform MORRISVILLE, N.C., March 20, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the Company’s financial results for the fourth quarter and full year 2016. Total operating expenses for the three months ended Dec. 31, 2016, were approximately $13.1 million, which includes research and development, or R&D, expenses totaling approximately $9.1 million and general and admi... 
03/06/17Novan Provides Update on SB204 Development Program
Company to Host Conference Call and Webcast to Provide Additional Results of Phase 3 Clinical Trials MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302 pivotal clinical trials for the Company’s topical nitric oxide-releasing product candidate, SB204, it intends to proceed with the SB204 development program. Following announcement of the top-line re... 
03/03/17Novan Announces SB204 Program Update Conference Call and Webcast
MORRISVILLE, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m. Eastern Time to provide an update on the SB204 development program. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the United States... 
03/02/17Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
Abstract Accepted for Late-breaking Research Presentation by Dr. Stephen Tyring MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV, will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology, or AAD, in Orlando, Florida. S... 
03/01/17Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
Preclinical Data Showed Significant Inhibition of High-Risk HPV-18 and Reduction of E6 Viral Protein MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company's nitric oxide-releasing drug candidates will be presented at the 31st International Papillomavirus Conference in Cape Town, South Africa. Thomas Broker, Ph.D., and Louise Chow, Ph.D., both of the Uni... 
01/27/17Novan Reports Topline Results from SB204 Phase 3 Pivotal Trials
Topical Acne Product Candidate Achieves Statistical Significance on All Three Co-Primary Endpoints in One Trial, Demonstrates Statistical Significance on Only One of Three in the Second Company Continues to Analyze Trial Data to Better Understand These Results MORRISVILLE, N.C., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) today announced  top-line results from the Company’s two, replicate Phase 3 pivotal clinical trials for SB204 in the treatment of acne vulgaris. In the ... 
01/17/17Novan Licenses SB204 to Sato for Acne in Japan
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a prescription pharmaceutical business specializing in dermatology. Upon execution of the agreement, Sato will pay to Novan an initial payment of 1.25 billion JPY (approximately $11.0 million) for the exclusive rights to develop and commercia...